Resection remains the cornerstone of curative treatment for gastric cancer, but it is associated with a cure rate of 25% to 35%. Recent positive results from large phase 3 trials1-3 leave the surgical oncologist with several options. Two accepted standards of care in the West focus on adjuvant CT-RT based on the North American Intergroup 0116 trial and perioperative CT based on the MAGIC trial from Britain.